Updated Jul 16, 2026
Huber Martin H. Jr. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $15K.
Martin H. Huber Jr. is an executive in the biopharmaceutical industry, currently serving as the Director, President, and CEO of Mersana Therapeutics, Inc. He has been involved in the development of antibody-drug conjugates aimed at improving cancer treatment.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | A — Grant or award | 24.0K | $0.00 | |
| 2025-09-11 | MRSN | Mersana Therapeutics, Inc. | S — Open-market sale | 2.0K | $7.31 | $15K |
| 2025-09-11 | MRSN | Mersana Therapeutics, Inc. | M — Option exercise | 6.7K | $0.00 |
Martin H. Huber Jr. is an executive in the biopharmaceutical industry, currently serving as the Director, President, and CEO of Mersana Therapeutics, Inc. He has been involved in the development of antibody-drug conjugates aimed at improving cancer treatment.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($15K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Huber Martin H. Jr. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.